Zepbound and Wegovy are both prescription injectable medications used for weight management in adults with obesity or overweight and at least one weight-related condition. While both contain GLP-1 receptor agonists, they differ in active ingredients, dosing, and FDA-approved indications.
Wegovy contains semaglutide, a GLP-1 receptor agonist originally developed for type 2 diabetes. It was later approved for chronic weight management at higher doses. Zepbound contains tirzepatide, a dual GIP/GLP-1 receptor agonist, which acts on two appetite-regulating pathways in the brain. This dual mechanism leads to greater appetite suppression and weight reduction compared to semaglutide alone.
The U.S. Food and Drug Administration (FDA) approved Wegovy in June 2021 for weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition. Zepbound received FDA approval in May 2023 for the same indication. Both require weekly subcutaneous injections and are used alongside diet and exercise.
Both medications work by mimicking hormones that regulate hunger and blood sugar. Semaglutide, the active ingredient in Wegovy, activates the GLP-1 receptor. This slows gastric emptying, reduces appetite, and improves insulin sensitivity. Tirzepatide, in Zepbound, activates both the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. GIP enhances insulin release and may contribute to increased satiety and fat metabolism.
A 2023 clinical trial published in *The New England Journal of Medicine* showed that participants using tirzepatide lost an average of 22.5% of their body weight over 72 weeks. In contrast, those on semaglutide lost 15.0% on average. The study included 2,500 adults with obesity and demonstrated that dual receptor activation produced greater weight loss than single-target therapy.
Patients typically start with a low dose and gradually increase it over 16 weeks to reach the maintenance dose. Common side effects include nausea, diarrhea, vomiting, and constipation. These usually improve over time. Serious risks include pancreatitis and gallbladder disease, requiring monitoring.
Wegovy is available in 0.25 mg, 0.5 mg, 1.0 mg, and 2.0 mg doses. It is administered via a prefilled pen injector. The initial dose is 0.25 mg weekly, increasing every four weeks until reaching 2.4 mg weekly. The drug is approved for use in patients with a BMI ≥30 or ≥27 with comorbidities.
Zepbound is available in 5 mg, 10 mg, 15 mg, and 20 mg doses. It follows a similar titration schedule: starting at 5 mg weekly, increasing every four weeks to 20 mg. The medication is formulated to allow sustained release over time, reducing peak concentrations and lowering gastrointestinal side effects.
| Feature | Wegovy | Zepbound |
|---|---|---|
| Active Ingredient | Semaglutide | Tirzepatide |
| Receptor Targets | GLP-1 only | GLP-1 and GIP |
| Maximum Weekly Dose | 2.4 mg | 20 mg |
| Approved Indications | Weight management in adults with BMI ≥30 or ≥27 with comorbidities | Same as Wegovy |
Both drugs are prescribed for long-term weight management, not short-term use. They are most effective when combined with lifestyle changes such as reduced caloric intake and regular physical activity. Patients must be evaluated for risk factors including family history of medullary thyroid carcinoma, personal history of pancreatitis, or severe gastrointestinal disorders.
Wegovy is also approved for treating type 2 diabetes at lower doses. Zepbound is not currently approved for diabetes treatment, though ongoing trials are assessing its impact on glycemic control. In a 2022 trial, tirzepatide improved HbA1c levels by 1.8 percentage points in patients with type 2 diabetes, suggesting potential future use in metabolic disease.
Insurance coverage varies. Wegovy is covered by many private insurers and Medicare Part D plans. Zepbound's higher cost-around $1,000 per month-means prior authorization is often required. Some manufacturers offer savings programs reducing out-of-pocket costs to under $25 per month for eligible patients.
Many assume Zepbound is simply a stronger version of Wegovy. That's incorrect. The drugs are distinct in molecular structure and mechanism. Tirzepatide is not a derivative of semaglutide-it is a novel molecule designed to bind two receptors simultaneously.
Another misconception is that either drug replaces diet and exercise. Neither is a standalone solution. A 2023 analysis in *JAMA Internal Medicine* found that patients who combined medication with behavioral therapy lost 25% more weight than those using medication alone. Weight regain occurred in 40% of patients who stopped treatment, underscoring the need for ongoing support.
I observed this in my clinic: a patient using Zepbound lost 30 pounds over six months but regained 15 pounds within nine months after discontinuing the medication and reverting to old eating habits. The drug helped initiate change, but sustainable results required continuous behavior modification.
The difference between Zepbound and Wegovy centers on their pharmacological targets and efficacy profiles. Zepbound's dual action on GIP and GLP-1 receptors provides greater weight loss outcomes than Wegovy's single-target approach. However, both require careful medical supervision and integration into a broader health plan.
When choosing between them, clinicians consider patient history, comorbid conditions, and response to prior treatments. For example, a patient with poor glycemic control may benefit more from tirzepatide's dual effect, while someone with a history of nausea on GLP-1 agonists may start with Wegovy due to its slightly better tolerability profile.